0.05) both in AFS assay and MTT assay to detect the apoptosis of the cell lines. However, there was significant difference ( P

Purpose:The experimental study on the changes of HPV18 E6 gene,p53 mRNA and telomerase catalytic subunit (hTERT) mRNA in the process of HeLa cell apoptosis was carried out to supply a new way to diagnosing and treating cervical cancer. Methods:The apoptosis of HeLa cell was confirmed by means of electron microscope and flow cytometry. With PCR and RT PCR, we studied the changes and relations among HPV18 E6 DNA,p53 mRNA as well as hTERT mRNA in the process of HeLa cell apoptosis. Results:HPV18 E6 DNA and p53 mRNA had no changes but hTERT mRNA activation was inhibited by elemene emulsion. Conclusions:During apoptosis of HeLa cells induced by elemene emulsion, hTERT mRNA activation could apparently be inhibited. Hence, inhibition of telomerase activation may represent a new chemosensitisation for tumors resistant to anticancer drugs.

OBJECTIVETo explore the polymorphism in circumsporozoite protein of Plasmodium vivax before malaria was eliminated in Hainan island.

METHODSPCR amplification, sequencing, and alignment methodologies were conducted and phylogenetic tree constructed.

RESULTSFrom all the cases, 19 of them belonged to two types, with 18 as VK210 type and 1 as VK247 type. VK210 type could be divided into seven kinds of subtypes but VK247 had only one type. Ratio of tropical strain with temperate stain in VK210 type was explored between the two stages:control or elimination. Phylogenetic tree was constructed by amino acid sequencing which clearly manifested that VK210 type and VK247 type belonged to different clusters.

CONCLUSIONCompared the proportion of two types in the control stage, there was no significant difference seen in the stage of elimination.

China ; epidemiology ; Genotype ; Humans ; Malaria, Vivax ; epidemiology ; prevention & control ; Plasmodium vivax ; classification ; genetics ; isolation & purification ; Polymorphism, Genetic ; Spores, Protozoan ; genetics

BACKGROUND: Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). METHODS: This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. RESULTS: This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. CONCLUSIONS Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.